Fragile X syndrome (FXS) is a rare genetic disorder caused due to the mutations in the Fragile X mental retardation 1 (FMR1) gene. Also known as Martin-Bell syndrome, the disease occurs due to the absence of a protein – Fragile X mental retardation protein (FMRP) – required for normal development of the body.
DelveInsight’s “Fragile X Syndrome Pipeline Insight, 2020” report provides an in-depth view of present clinical development trends and growth prospects in the Fragile X Syndrome market.
The report covers the Fragile X Syndrome pipeline landscape including treatment guidelines, commercial assessment and clinical assessment. The report covers all the products from the pre-clinical developmental phase to the marketed phase, with a detailed description of the drug, mechanism of action, clinical studies, NDA approvals (if any), and product development activities.
The Fragile X Syndrome pipeline report also sheds light on the novel technologies, Fragile X Syndrome collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Robust Fragile X Syndrome Pipeline
Fragile X syndrome pipeline products comprise of several therapies such as ZYN002 (Zynerba Pharmaceuticals), STX209 (Seaside Therapeutics), OV101 (Ovid Therapeutics), Trofinetide (Neuren Pharmaceuticals), BPN14770 (Tetra Discovery Partners), and Bryostatin (Neurotrope Bioscience) that shall positively impact the Fragile X syndrome market during the study period (2017-2030).
- Comprehensive understanding of disease pathogenesis
- Novel therapies
- Changing Fragile X Syndrome market trends
- Companies and academics working in FXS market
- Challenges present and opportunities untapped in the Fragile X Syndrome market
- R&D influencing FXS market
- A detailed pharma players’ portfolio involved in fuelling the Fragile X Syndrome treatment market
- In-depth analysis of the pipeline assets
Table of Contents
1. Report Introduction
2. Fragile X Syndrome
3. Fragile X Syndrome Current Treatment Patterns
4. Fragile X Syndrome – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Fragile X Syndrome Late Stage Products (Phase-III)
7. Fragile X Syndrome Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Fragile X Syndrome Discontinued Products
13. Fragile X Syndrome Product Profiles
14. Fragile X Syndrome Key Companies
15. Fragile X Syndrome Key Products
16. Dormant and Discontinued Products
17. Fragile X Syndrome Unmet Needs
18. Fragile X Syndrome Future Perspectives
19. Fragile X Syndrome Analyst Review
21. Report Methodology
*The table of contents is not exhaustive; will be provided in the final report
DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.
Browse through our vast repository from here.
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States